Introduction {#sec1}
============

Nitrones and isocyanides constitute multifaceted building blocks in organic synthesis and have been extensively implemented in the construction of nitrogen-based heterocyclic compounds.^[@ref1],[@ref2]^ Thus far, several remarkable reaction manifolds have been realized. Among these, the \[3 + 2\] dipolar cycloaddition reaction represents a powerful strategy to access five-membered heterocyclic compounds owing to its simplicity and atom efficiency.^[@ref3],[@ref4]^ In contrast, \[3 + 1\] and \[3 + 1 + 1\] cycloaddition reactions of nitrones with isocyanides to assemble heterocycles have rarely been utilized.^[@ref5]−[@ref8]^

Only a handful of reports detailing the cycloaddition manifolds of nitrones with isocyanides have been disclosed ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}a). For example, the Zhu, Zeeh, and Lorke groups have demonstrated that nitrones can undergo \[3 + 1\] cycloaddition with isocyanides to afford four-membered 4-imino-1,2-oxazetidine motifs.^[@ref6]^ Furthermore, a proposed \[3 + 3\] cycloaddition process involving nitrones and α-metalated isocyanides to produce five-membered 2-imidazolidinones was recently reported.^[@ref8]^ Also, Xu and co-workers realized that isocyanoacetates could react with nitrones to produce polysubstituted pyrroles in the presence of commercially available copper salts through a \[3 + 1 + 1\] cycloaddition manifold.^[@ref7]^ Luzyanin and co-workers have also described a metal-mediated strategy in which nitrones react with palladium-bound isocyanides to provide carbene complexes ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}b).^[@ref9]^ Despite the number of synthetic methodologies that have been realized,^[@ref10]^ the development of new and efficient methods that rely on easily available starting materials are of great value. As a continuation of the recently witnessed reports on isocyanide-involving reaction manifolds,^[@ref11]^ we have explored silver-mediated manifolds involving isocyanides.^[@ref12]^ Here, we disclose a silver-assisted \[3 + 2\] annulation reaction of nitrones with isocyanides for the assembly of 1,2,4-oxadiazolidin-5-ones and the subsequent decarboxylative process for accessing amidines, which are vital motifs in pharmaceuticals and natural products.^[@ref13]^ The developed methods display broad substrate scope and are conducted under mild reaction conditions ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}c).

![Annulation reactions of isocyanides with nitrones.](jo9b03279_0001){#fig1}

Results and Discussion {#sec2}
======================

*N*-Benzylideneaniline oxide (**1a**) and 1-bromo-4-isocyanobenzene (**2a**) were selected as model substrates for the optimization of the \[3 + 2\] annulation reaction. To our delight, conducting the reaction in DMF at 80 °C in the presence of Ag~2~O (10 mol %) afforded the desired product 4-(4-bromophenyl)-2,3-diphenyl-1,2,4-oxadiazolidin-5-one (**3a**) in a 76% isolated yield after merely 4 h ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 1). Screening of other silver salts, including AgOAc, Ag~2~CO~3~, AgOTf, AgBF~4~, and other metal precursors, such as CuI and Pd(OAc)~2~, showed that Ag~2~CO~3~ and Ag~2~O displayed the best reactivity while AgOAc proved to be less efficient and the other metal catalysts were inactive ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 2--7). Next, switching to 1,4-dioxane greatly increased the yield of annulation adduct **3a** to 91% ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 8). The use of aprotic or polar solvents, such as toluene and MeCN, had a negative effect on the reaction and delivered **3a** in diminished yields ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 9 and 10) while employing the protic solvent EtOH nearly inhibited the reaction ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 11). Decreasing the reaction temperature from 80 to 40 °C led to a significantly diminished yield of the desired product ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 12). A control experiment established that a silver catalyst is required for the reaction to proceed ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 13). Furthermore, the annulation affords product **3a** as a single diastereomer as confirmed by single-crystal X-ray diffraction analysis (CCDC 1915298, see [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).

![Silver-Assisted Synthesis of Oxadiazolidinones\
All reactions were carried out with **1a** (0.55 mmol), **2a** (0.5 mmol), and Ag~2~O (10 mol %) in 1,4-dioxane (2.0 mL) at 80 °C under air for 4 h. Yields are of isolated products after purification by column chromatography. Products were isolated as single diastereomers.](jo9b03279_0002){#sch1}

###### Optimization of the Reaction Conditions[a](#t1fn1){ref-type="table-fn"}^,^[b](#t1fn2){ref-type="table-fn"}

![](jo9b03279_0006){#GRAPHIC-d7e369-autogenerated}

  entry   \[M\]                solvent           temp (°C)   yield (%)[b](#t1fn2){ref-type="table-fn"}
  ------- -------------------- ----------------- ----------- -------------------------------------------
  1       Ag~2~O               DMF               80          76
  2       AgOAc                DMF               80          42
  3       Ag~2~CO~3~           DMF               80          74
  4       AgOTf                DMF               80          \<5[c](#t1fn3){ref-type="table-fn"}
  5       AgBF~4~              DMF               80          \<5[c](#t1fn3){ref-type="table-fn"}
  6       CuI                  DMF               80          \<5[c](#t1fn3){ref-type="table-fn"}
  7       Pd(OAc)~2~           DMF               80          \<5[c](#t1fn3){ref-type="table-fn"}
  **8**   **Ag**~**2**~**O**   **1,4-dioxane**   **80**      **91**
  9       Ag~2~O               toluene           80          76
  10      Ag~2~O               CH~3~CN           80          53
  11      Ag~2~O               EtOH              80          \<10[c](#t1fn3){ref-type="table-fn"}
  12      Ag~2~O               1,4-dioxane       40          38
  13                           1,4-dioxane       80          \<5[c](#t1fn3){ref-type="table-fn"}

Reaction conditions: all reactions were carried out with **1a** (0.55 mmol), **2a** (0.5 mmol), catalyst (10 mol %) in the solvent (2.0 mL) under air for 4 h.

Yield are of isolated **3a** after purification by column chromatography.

Yield determined by ^1^H NMR analysis of the reaction mixture using CH~2~Br~2~ as the internal standard.

Next, the optimal reaction conditions were adopted on a variety of nitrones and aryl isocyanides to investigate the generality of the protocol ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). A collection of diversely functionalized nitrones underwent annulation with aryl isocyanides to deliver the corresponding product **3** in good to excellent yields. For example, para-substituted arene motifs bearing electron-donating or electron-withdrawing moieties were tolerated in the annulation with 1-bromo-4-isocyanobenzene (**2a**) to produce the corresponding products (**3b**--**3g**) in high yields. Similarly, ortho-, meta-, and disubstituted substrates were also well tolerated, affording products **3h**--**3n** in good to high yields. Gratifyingly, common functional groups including alkyl, alkoxy, halogen, cyano, and trifluoromethyl were all effective. A more elaborate substrate (**1p**) with a potentially sensitive alkyne moiety could also be successfully converted to product **3p** (72%), illustrating the compatibility of the developed method. Heteroaryl nitrones including 2-furyl and 2-thienyl were also evaluated, delivering the corresponding adducts **3t** and **3u** with high efficiency. Furthermore, subjecting the fused aromatic (**1v**) or alkyl (**1w** and **1x**) nitrones to isocyanide **2a**, afforded the desired products **3v**--**3x** in good to excellent yields. The protocol also tolerated a wide variation of substituents on the arene ring on the isocyanides (**2y**--**2ad**), efficiently delivering a set of diverse oxadiazolidinones (**3y**--**3ad**) in high yields. The applicability of the annulation protocol was highlighted through a gram-scale reaction of *N*-benzylideneaniline oxide (**1a**) and 1-bromo-4-isocyanobenzene (**2a**). The reaction was performed on a 10 mmol scale and proceeded smoothly to give product **3a** (3.26 g, 83%) even when decreasing the amount of the catalyst to 5 mol % ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).

We further explored the application of the synthesized oxadiazolidinones. Intriguingly, subjecting **3a**, **3y**, **3z**, **3ab**, and **3ac** to Cs~2~CO~3~ (2.0 equiv) triggered extrusion of CO~2~ to give amidines **4a**--**4e** in up to 92% yield ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). Compared to Anderson's reaction conditions,^[@cit10d]^ no reaction occurred using compound **3** even when extending the reaction time to 24 h. Therefore, the developed protocol undoubtedly represents a more general and practical methodology to access amidines, complementing the existing ones.

![Application of Oxadiazolidinones to the Synthesis of Amidines through CO~2~ Extrusion](jo9b03279_0003){#sch2}

A series of mechanistic experiments was performed to gain insights into the reaction mechanism ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}). The key step is clearly to derive the source of the carbonyl oxygen that is incorporated in oxadiazolidinone **3**. Therefore, experiments were carried out with **1c** and **2a** under the optimized reaction conditions with the addition of 2.0 equiv of H~2~^18^O ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}a). In the presence of H~2~^18^O, the reaction between **1c** and **2a** only provides \[^16^O\]-**3c**; albeit with a decreased yield.^[@ref14]^ This implies that O~2~ is the oxygen source in this reaction. Meanwhile, a decreased yield of product **3c** was obtained when carrying out the reaction under N~2~, highlighting that O~2~ is necessary for the reaction to proceed efficiently ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}b).

![Mechanistic Investigations](jo9b03279_0004){#sch3}

Based on the results from the described experiments and related literature precedents,^[@ref2],[@ref15]^ a plausible mechanism was proposed ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}). Initially, isocyanide **2** coordinates to the silver center, generating silver intermediate **A**.^[@ref16]^ Then, it is believed that nitrone **1** attacks complex **A**, producing intermediate **B**. This species presumably undergoes rapid intramolecular cyclization to generate the five-membered cyclized cationic intermediate **C**.^[@ref17]^ Subsequent protodeargentation of intermediate **C** produces **D**, which is oxidized by O~2~,^[@ref18]^ delivering product **3** with the regeneration of water and completing the catalytic cycle. Thus, the protodeargentation step can be initiated by residual water present in the solvent or air (cf. [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).

![Proposed Reaction Mechanism for the Formation of Oxadiazolidinone **3**](jo9b03279_0005){#sch4}

Conclusions {#sec3}
===========

In summary, we have developed a silver-assisted protocol for \[3 + 2\] annulation between isocyanides and nitrones, providing a convenient approach for the construction of 2,3,4-trisubstituted 1,2,4-oxadiazolidin-5-ones in good to excellent yields. The reaction mechanism is proposed to proceed through a nucleophilic addition/cyclization/protodeargentation/oxidation pathway. Finally, base-promoted decarboxylation of the prepared oxadiazolidinones at ambient temperature is also described, providing a convenient protocol for the direct assembly of amidine compounds.

Experimental Section {#sec4}
====================

General Information {#sec4.1}
-------------------

All reagents were purchased from commercial suppliers and used without treatment, unless otherwise indicated. The products were purified by column chromatography on silica gel. ^1^H NMR and ^13^C NMR spectra were recorded on a Varian NMR spectrometer at 400 and 101 MHz, respectively. NMR spectra for compounds **3a**--**3ad** were recorded in CDCl~3~, while compounds **4a**--**4e** displayed spectra containing signals from multiple tautomeric forms and geometrical isomers; however, good quality NMR spectra for these compounds were obtained in CDCl~3~ upon the addition of a small amount of D~2~SO~4~. Mass spectra were recorded on a BRUKER Autoflex III Smartbeam MS-spectrometer. High-resolution mass spectra (HRMS) were recorded on a Bruker micrOTOF using atmospheric pressure chemical ionization (APCI) or electrospray ionization (ESI) methods.

General Procedure for Synthesis of 1,2,4-Oxadiazolidin-5-ones (with **3a** as an Example) {#sec4.2}
-----------------------------------------------------------------------------------------

A 10 mL Schlenk flask equipped with a magnetic stir bar was charged with a mixture of **1a** (108 mg, 0.55 mmol), **2a** (90 mg, 0.5 mmol), and 1,4-dioxane (2.0 mL). Then, Ag~2~O (12 mg, 10 mol %) was added and the mixture was stirred at 80 °C in an oil bath until substrate **2a** was consumed as indicated by thin layer chromatography (TLC) (about 4 h). The resulting mixture was concentrated and the residue was taken up in CH~2~Cl~2~. The organic layer was washed with brine, dried over MgSO~4~, and concentrated. Purification of the crude product by column chromatography (silica gel; petroleum ether/ethyl acetate 10:1) afforded **3a** as a white solid (179 mg, 91%).

General Procedure for Synthesis of Amidines (with **4a** as an Example) {#sec4.3}
-----------------------------------------------------------------------

A 10 mL Schlenk flask equipped with a magnetic stir bar was charged with a mixture of **3a** (197 mg, 0.5 mmol) and Cs~2~CO~3~ (325 mg, 1 mmol, 2.0 equiv). Then, EtOH (2.0 mL) was added and the mixture was stirred at room temperature until substrate **3a** was consumed as indicated by TLC (about 30 min). The resulting mixture was concentrated and the residue was taken up in CH~2~Cl~2~. The organic layer was washed with brine, dried over MgSO~4~, and concentrated. Purification of the crude product by column chromatography (silica gel; petroleum ether/ethyl acetate 10:3) afforded **4a** as a white solid (147 mg, 84%).

### 4-(4-Bromophenyl)-2,3-diphenyl-1,2,4-oxadiazolidin-5-one (**3a**) {#sec4.3.1}

The product was obtained in a 91% yield (179 mg). White solid; mp 139--140 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.50--7.47 (m, 2H), 7.45--7.43 (m, 3H), 7.41--7.36 (m, 4H), 7.24--7.19 (m, 5H), 6.11 (s, 1H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 154.0, 149.1, 135.2, 134.7, 132.2, 130.2, 129.5, 129.4, 127.1, 125.9, 122.4, 118.8, 117.4, 86.3; HRMS (APCI) *m*/*z*: calcd for C~20~H~16~BrN~2~O~2~ \[M + H\]^+^, 395.0390; found, 395.0370.

### 4-(4-Bromophenyl)-2-phenyl-3-(*p*-tolyl)-1,2,4-oxadiazolidin-5-one (**3b**) {#sec4.3.2}

The product was obtained in a 92% yield (187 mg). White solid; mp 138--139 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.41--7.36 (m, 6H), 7.25--7.19 (m, 7H), 6.07 (s, 1H), 2.37 (s, 3H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 154.0, 149.1, 140.4, 134.7, 132.2, 132.15, 130.0, 129.4, 127.1, 125.8, 122.5, 118.7, 117.4, 86.3, 21.3; HRMS (APCI) *m*/*z*: calcd for C~21~H~18~BrN~2~O~2~ \[M + H\]^+^, 409.0552; found, 409.0531.

### 4-(4-Bromophenyl)-3-(4-chlorophenyl)-2-phenyl-1,2,4-oxadiazolidin-5-one (**3c**) {#sec4.3.3}

The product was obtained in a 87% yield (186 mg). White solid; mp 160--161 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.42--7.38 (m, 8H), 7.26--7.16 (m, 5H), 6.08 (s, 1H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 153.8, 148.8, 136.3, 134.4, 133.7, 132.4, 129.6, 129.5, 128.6, 126.2, 122.6, 119.1, 117.5, 85.6; HRMS (APCI) *m*/*z*: calcd for C~20~H~15~BrClN~2~O~2~ \[M + H\]^+^, 429.0005; found, 429.0017.

### 3,4-Bis(4-bromophenyl)-2-phenyl-1,2,4-oxadiazolidin-5-one (**3d**) {#sec4.3.4}

The product was obtained in a 89% yield (209 mg). White solid; mp 168--169 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.58 (d, *J* = 8.4 Hz, 2H), 7.42--7.35 (m, 6H), 7.25--7.16 (m, 5H), 6.07 (s, 1H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 153.8, 148.8, 134.4, 134.2, 132.6, 132.4, 129.5, 128.9, 126.2, 124.6, 122.6, 119.2, 117.5, 85.7; HRMS (APCI) *m*/*z*: calcd for C~20~H~15~Br~2~N~2~O~2~ \[M + H\]^+^, 472.9500; found, 472.9471.

### 4-(4-Bromophenyl)-3-(4-fluorophenyl)-2-phenyl-1,2,4-oxadiazolidin-5-one (**3e**) {#sec4.3.5}

The product was obtained in a 86% yield(177 mg). White solid; mp 150--151 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.49--7.45 (m, 2H), 7.41--7.37 (m, 4H), 7.24--7.18 (m, 4H), 7.16--7.10 (m, 3H), 6.10 (s, 1H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 85.7, 116.5 (d, *J*~(F--C)~ = 21.9 Hz), 117.5, 119.1, 122.7, 126.1, 129.2 (d, *J*~(F--C)~ = 8.5 Hz), 129.5, 131.1 (d, *J*~(F--C)~ = 3.2 Hz), 132.3, 134.4, 148.8, 153.8, 163.6 (d, *J*~(F--C)~ = 248.9 Hz); HRMS (APCI) *m*/*z*: calcd for C~20~H~15~BrFN~2~O~2~ \[M + H\]^+^, 413.0301; found, 413.0300.

### 4-(4-Bromophenyl)-2-phenyl-3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazolidin-5-one (**3f**) {#sec4.3.6}

The product was obtained in a 79% yield (182 mg). White solid; mp 164--165 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.72 (d, *J* = 8.0 Hz, 2H), 7.62 (d, *J* = 8.0 Hz, 2H), 7.44--7.41 (m, 4H), 7.27--7.23 (m, 3H), 7.20--7.18 (m, 2H), 6.18 (s, 1H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 153.8, 148.9, 139.2, 134.4, 132.5, 132.2, 129.7, 127.6, 126.4, 124.9, 122.4, 122.2, 119.2, 117.5, 85.5; HRMS (APCI) *m*/*z*: calcd for C~21~H~15~BrF~3~N~2~O~2~ \[M + H\]^+^, 463.0269; found, 463.0276.

### 4-(4-(4-Bromophenyl)-5-oxo-2-phenyl-1,2,4-oxadiazolidin-3-yl)benzonitrile (**3g**) {#sec4.3.7}

The product was obtained in a 63% yield (132 mg). White solid; mp 144--145 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.74 (d, *J* = 8.4 Hz, 2H), 7.61 (d, *J* = 8.0 Hz, 2H), 7.44--7.40 (m, 4H), 7.28--7.22 (m, 3H), 7.17 (d, *J* = 8.8 Hz, 2H), 6.17 (s, 1H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 153.6, 148.7, 140.2, 134.2, 133.1, 132.6, 129.7, 127.9, 126.5, 122.4, 119.4, 117.8, 117.5, 114.3, 85.2; HRMS (APCI) *m*/*z*: calcd for C~21~H~15~BrN~3~O~2~ \[M + H\]^+^, 420.0348; found, 420.0353.

### 4-(4-Bromophenyl)-3-(3-methoxyphenyl)-2-phenyl-1,2,4-oxadiazolidin-5-one (**3h**) {#sec4.3.8}

The product was obtained in a 85% yield (180 mg). White solid; mp 124--125 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.41--7.32 (m, 5H), 7.25--7.19 (m, 5H), 7.05--7.03 (m, 2H), 6.97--6.95 (m, 1H), 6.07 (s, 1H), 3.80 (s, 3H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 160.3, 153.9, 149.1, 136.7, 134.6, 132.2, 130.5, 129.4, 125.9, 122.4, 119.3, 118.8, 117.3, 115.5, 112.7, 86.2, 55.4; HRMS (APCI) *m*/*z*: calcd for C~21~H~18~BrN~2~O~3~ \[M + H\]^+^, 425.0501; found, 425.0509.

### 4-(4-Bromophenyl)-3-(3-chlorophenyl)-2-phenyl-1,2,4-oxadiazolidin-5-one (**3i**) {#sec4.3.9}

The product was obtained in a 81% yield (173 mg). White solid; mp 161--163 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.51 (s, 1H), 7.43--7.39 (m, 5H), 7.38--7.33 (m, 2H), 7.25--7.18 (m, 5H), 6.08 (s, 1H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 153.8, 148.9, 137.4, 135.4, 134.4, 132.4, 130.7, 130.5, 129.6, 127.3, 126.2, 125.2, 122.4, 119.1, 117.4, 85.5; HRMS (APCI) *m*/*z*: calcd for C~20~H~15~BrClN~2~O~2~ \[M + H\]^+^, 429.0005; found, 429.0011.

### 4-(4-Bromophenyl)-3-(2-chlorophenyl)-2-phenyl-1,2,4-oxadiazolidin-5-one (**3j**) {#sec4.3.10}

The product was obtained in a 84% yield (179 mg). White solid; mp 120--121 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.50 (d, *J* = 7.6 Hz, 2H), 7.44--7.33 (m, 8H), 7.24--7.21 (m, 3H), 6.70 (s, 1H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 154.4, 149.3, 134.5, 133.3, 132.4, 132.3, 131.5, 130.5, 129.5, 128.1, 127.9, 126.1, 121.3, 118.6, 117.5, 81.9; HRMS (APCI) *m*/*z*: calcd for C~20~H~15~BrClN~2~O~2~ \[M + H\]^+^, 429.0005; found, 429.0008.

### 3-(2-Bromophenyl)-4-(4-bromophenyl)-2-phenyl-1,2,4-oxadiazolidin-5-one (**3k**) {#sec4.3.11}

The product was obtained in a 85% yield (200 mg). Yellow oil; ^1^H NMR (400 MHz, CDCl~3~): δ 7.66 (d, *J* = 8.0 Hz, 1H), 7.52 (d, *J* = 7.6 Hz, 1H), 7.42--7.39 (m, 7H), 7.33--7.29 (m, 1H), 7.25--7.21 (m, 3H), 6.69 (s, 1H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 154.4, 149.1, 134.4, 133.9, 133.8, 132.3, 131.7, 129.5, 128.8, 128.3, 126.2, 123.2, 121.6, 118.7, 117.9, 84.0; HRMS (APCI) *m*/*z*: calcd for C~20~H~15~Br~2~N~2~O~2~ \[M + H\]^+^, 472.9500; found, 472.9504.

### 4-(4-Bromophenyl)-3-(2-methoxyphenyl)-2-phenyl-1,2,4-oxadiazolidin-5-one (**3l**) {#sec4.3.12}

The product was obtained in a 93% yield (197 mg). White solid; mp 128--129 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.43--7.35 (m, 7H), 7.30--7.28 (m, 1H), 7.26--7.24 (m, 2H), 7.20--7.16 (m, 1H), 7.03--6.97 (m, 2H), 6.66 (s, 1H), 4.00 (s, 3H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 157.1, 154.6, 150.2, 135.1, 132.1, 131.4, 129.3, 126.8, 125.3, 122.8, 121.3, 120.8, 117.9, 116.6, 111.3, 80.7, 55.7; HRMS (APCI) *m*/*z*: calcd for C~21~H~18~BrN~2~O~3~ \[M + H\]^+^, 425.0501; found, 425.0470.

### 4-(4-Bromophenyl)-3-(2,4-dichlorophenyl)-2-phenyl-1,2,4-oxadiazolidin-5-one (**3m**) {#sec4.3.13}

The product was obtained in a 88% yield (195 mg). White solid; mp 109--110 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.52--7.51 (m, 1H), 7.46--7.40 (m, 5H), 7.37--7.33 (m, 3H), 7.24--7.19 (m, 3H), 6.64 (s, 1H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 154.2, 149.0, 137.0, 134.2, 134.0, 132.5, 131.1, 130.4, 129.6, 129.0, 128.6, 126.3, 121.5, 118.9, 117.6, 81.5; HRMS (APCI) *m*/*z*: calcd for C~20~H~14~BrCl~2~N~2~O~2~ \[M + H\]^+^, 462.9616; found, 462.9622.

### 3-(2-Bromo-4-chlorophenyl)-4-(4-bromophenyl)-2-phenyl-1,2,4-oxadiazolidin-5-one (**3n**) {#sec4.3.14}

The product was obtained in a 94% yield (229 mg). White solid; mp 108--109 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.67 (d, *J* = 1.6 Hz, 1H), 7.48--7.37 (m, 8H), 7.27--7.23 (m, 1H), 7.21--7.19 (m, 2H), 6.64 (s, 1H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 154.2, 148.7, 137.0, 134.1, 133.4, 132.5, 132.4, 129.5, 129.2, 129.1, 126.4, 123.6, 121.7, 118.9, 117.9, 83.5; HRMS (APCI) *m*/*z*: calcd for C~20~H~14~Br~2~ClN~2~O~2~ \[M + H\]^+^, 506.9105; found, 506.9122.

### 3-(Benzo\[*d*\]\[1,3\]dioxol-5-yl)-4-(4-bromophenyl)-2-phenyl-1,2,4-oxadiazolidin-5-one (**3o**) {#sec4.3.15}

The product was obtained in a 93% yield (203 mg). White solid; mp 141--142 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.41--7.36 (m, 4H), 7.23--7.18 (m, 5H), 7.00 (s, 1H), 6.90 (d, *J* = 8.0 Hz, 1H), 6.81 (d, *J* = 8.0 Hz, 1H), 6.01--6.005 (m, 2H), 5.99 (s, 1H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 153.8, 149.3, 148.8, 134.6, 132.3, 129.4, 128.9, 126.0, 122.9, 121.7, 119.0, 117.6, 108.6, 107.2, 101.7, 86.3, 29.7; HRMS (APCI) *m*/*z*: calcd for C~21~H~16~BrN~2~O~4~ \[M + H\]^+^, 439.0293; found, 439.0297.

### 4-(4-Bromophenyl)-3-(2-((4-methoxyphenyl)ethynyl)-4-methylphenyl)-2-phenyl-1,2,4-oxadiazolidin-5-one (**3p**) {#sec4.3.16}

The product was obtained in a 72% yield (193 mg). White solid; mp 168--169 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.46 (s, 1H), 7.43--7.41 (m, 5H), 7.38--7.35 (m, 2H), 7.33--7.29 (m, 4H), 7.20--7.14 (m, 2H), 6.90 (d, *J* = 8.4 Hz, 2H), 6.82 (s, 1H), 3.85 (s, 3H), 2.36 (s, 3H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 160.2, 154.2, 149.6, 140.2, 134.8, 133.5, 133.1, 133.06, 132.2, 130.3, 129.3, 126.3, 125.6, 122.9, 121.3, 118.2, 117.3, 114.2, 96.0, 85.2, 83.3, 55.4, 21.1; HRMS (APCI) *m*/*z*: calcd for C~30~H~24~BrN~2~O~3~ \[M + H\]^+^, 539.0965; found, 539.0973.

### 4-(4-Bromophenyl)-3-phenyl-2-(*m*-tolyl)-1,2,4-oxadiazolidin-5-one (**3q**) {#sec4.3.17}

The product was obtained in a 85% yield (173 mg). White solid; mp 164--165 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.50--7.43 (m, 5H), 7.38 (d, *J* = 8.8 Hz, 2H), 7.29--7.25 (m, 1H), 7.21 (d, *J* = 8.8 Hz, 2H), 7.07 (s, 1H), 7.03--7.01 (m, 2H), 6.11 (s, 1H), 2.37 (s, 3H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 154.1, 149.3, 139.6, 135.3, 134.8, 132.2, 130.2, 129.3, 129.26, 127.1, 126.7, 122.3, 118.7, 117.9, 114.3, 86.3, 21.6; HRMS (APCI) *m*/*z*: calcd for C~21~H~18~BrN~2~O~2~ \[M + H\]^+^, 409.0552; found, 409.0563.

### 2,4-Bis(4-bromophenyl)-3-phenyl-1,2,4-oxadiazolidin-5-one (**3r**) {#sec4.3.18}

The product was obtained in a 89% yield (209 mg). White solid; mp 153--154 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.51--7.49 (m, 2H), 7.47--7.43 (m, 5H), 7.40--7.38 (m, 2H), 7.17 (d, *J* = 8.8 Hz, 2H), 7.09 (d, *J* = 8.8 Hz, 2H), 6.05 (s, 1H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 153.6, 148.0, 134.7, 134.4, 132.5, 132.3, 130.5, 129.4, 127.2, 122.7, 119.1, 119.0, 86.3; HRMS (APCI) *m*/*z*: calcd for C~20~H~15~Br~2~N~2~O~2~ \[M + H\]^+^, 472.9500; found, 472.9513.

### 4-(4-Bromophenyl)-3-phenyl-2-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazolidin-5-one (**3s**) {#sec4.3.19}

The product was obtained in a 77% yield (178 mg). White solid; mp 134--135 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.65 (d, *J* = 8.4 Hz, 2H), 7.51--7.46 (m, 5H), 7.40 (d, *J* = 8.8 Hz, 2H), 7.29 (d, *J* = 8.4 Hz, 2H), 7.17 (d, *J* = 8.8 Hz, 2H), 6.15 (s, 1H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 153.2, 151.8, 134.7, 134.2, 132.4, 130.6, 129.5, 127.2, 126.8, 126.7, 122.9, 119.4, 116.6, 86.1; HRMS (APCI) *m*/*z*: calcd for C~21~H~15~BrF~3~N~2~O~2~ \[M + H\]^+^, 463.0269; found, 463.0271.

### 4-(4-Bromophenyl)-3-(furan-2-yl)-2-phenyl-1,2,4-oxadiazolidin-5-one (**3t**) {#sec4.3.20}

The product was obtained in a 86% yield (165 mg), yellow oil; ^1^H NMR (400 MHz, CDCl~3~): δ 7.51 (s, 1H), 7.44--7.39 (m, 4H), 7.28--7.20 (m, 5H), 6.54--6.53 (m, 1H), 6.42--6.41 (m, 1H), 6.21 (s, 1H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 153.7, 149.0, 147.9, 144.3, 134.6, 132.3, 129.5, 125.9, 121.9, 118.9, 117.1, 111.0, 110.6, 79.9; HRMS (APCI) *m*/*z*: calcd for C~18~H~14~BrN~2~O~3~ \[M + H\]^+^, 385.0188; found, 385.0197.

### 4-(4-Bromophenyl)-2-phenyl-3-(thiophen-2-yl)-1,2,4-oxadiazolidin-5-one (**3u**) {#sec4.3.21}

The product was obtained in a 81% yield (162 mg). Yellow oil; ^1^H NMR (400 MHz, CDCl~3~): δ 7.45--7.38 (m, 5H), 7.25--7.21 (m, 5H), 7.15--7.14 (m, 1H), 7.01--6.99 (m, 1H), 6.38 (s, 1H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 153.4, 148.5, 138.6, 134.3, 132.4, 129.5, 128.3, 127.9, 127.1, 126.1, 123.2, 119.4, 117.5, 82.4; HRMS (APCI) *m*/*z*: calcd for C~18~H~14~BrN~2~O~2~S \[M + H\]^+^, 400.9959; found, 400.9967.

### 4-(4-Bromophenyl)-3-(naphthalen-1-yl)-2-phenyl-1,2,4-oxadiazolidin-5-one (**3v**) {#sec4.3.22}

The product was obtained in a 90% yield (200 mg). White solid; mp 164--165 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.20 (d, *J* = 8.4 Hz, 1H), 7.97--7.93 (m, 2H), 7.65--7.55 (m, 3H), 7.49--7.45 (m, 1H), 7.42--7.38 (m, 2H), 7.34--7.24 (m, 5H), 7.20--7.16 (m, 2H), 6.88 (s, 1H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 154.5, 148.7, 134.8, 134.3, 132.2, 131.1, 130.6, 129.6, 129.5, 129.2, 127.3, 126.7, 126.3, 126.2, 125.3, 122.2, 122.1, 119.0, 118.7, 82.9; HRMS (APCI) *m*/*z*: calcd for C~24~H~18~BrN~2~O~2~ \[M + H\]^+^, 445.0546; found, 445.0558.

### 4-(4-Bromophenyl)-3-cyclohexyl-2-phenyl-1,2,4-oxadiazolidin-5-one (**3w**) {#sec4.3.23}

The product was obtained in a 62% yield (124 mg). White solid; mp 185--186 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.47 (d, *J* = 8.8 Hz, 2H), 7.40--7.36 (m, 2H), 7.32 (d, *J* = 8.8 Hz, 2H), 7.19--7.15 (m, 3H), 5.16 (d, *J* = 3.2 Hz, 1H), 1.85--1.82 (m, 4H), 1.76--1.70 (m, 2H), 1.54--1.39 (m, 2H), 1.33--1.22 (m, 2H), 1.19--1.16 (m, 1H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 154.3, 151.0, 135.0, 132.5, 129.4, 125.2, 122.3, 118.5, 116.3, 88.9, 40.6, 28.9, 26.0, 25.5; HRMS (APCI) *m*/*z*: calcd for C~20~H~22~BrN~2~O~2~ \[M + H\]^+^, 401.0859; found, 401.0866.

### 4-(4-Bromophenyl)-3-(cyclohex-3-en-1-yl)-2-phenyl-1,2,4-oxadiazolidin-5-one (**3x**) {#sec4.3.24}

The product was obtained in a 71% yield (141 mg). White solid; mp 162--163 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.48--7.46 (m, 2H), 7.41--7.37 (m, 2H), 7.32 (d, *J* = 8.4 Hz, 2H), 7.21--7.17 (m, 3H), 5.70--5.69 (m, 2H), 5.28--5.25 (m, 1H), 2.37--1.93 (m, 6H), 1.81--1.62 (m, 1H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 154.3, 150.8, 134.9, 132.5, 129.5, 127.4, 126.5, 125.3, 125.1, 122.6, 116.4, 88.6, 37.1, 27.3, 24.7, 22.0; HRMS (APCI) *m*/*z*: calcd for C~20~H~20~BrN~2~O~2~ \[M + H\]^+^, 399.0703; found, 399.0709.

### 2,3,4-Triphenyl-1,2,4-oxadiazolidin-5-one (**3y**) {#sec4.3.25}

The product was obtained in a 90% yield (142 mg). White solid; mp 101--102 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.70--7.08 (m, 15H), 6.21 (s, 1H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 154.3, 149.5, 135.8, 135.7, 130.1, 129.5, 129.31, 129.3, 127.2, 125.8, 125.7, 121.1, 117.3, 86.5; HRMS (APCI) *m*/*z*: calcd for C~20~H~17~N~2~O~2~ \[M + H\]^+^, 317.1285; found, 317.1293.

### 2,3-Diphenyl-4-(*m*-tolyl)-1,2,4-oxadiazolidin-5-one (**3z**) {#sec4.3.26}

The product was obtained in a 87% yield (143 mg). White solid; mp 108--109 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.53--7.50 (m, 2H), 7.45--7.37 (m, 5H), 7.27--7.25 (m, 2H), 7.22--7.18 (m, 2H), 7.16--7.12 (m, 1H), 7.02 (d, *J* = 8.0 Hz, 1H), 6.93 (d, *J* = 7.2 Hz, 1H), 6.14 (s, 1H), 2.27 (s, 3H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 154.3, 149.5, 139.3, 135.9, 135.5, 130.0, 129.4, 129.2, 129.0, 127.1, 126.5, 125.7, 121.7, 118.0, 117.2, 86.5, 21.4; HRMS (APCI) *m*/*z*: calcd for C~21~H~19~N~2~O~2~ \[M + H\]^+^, 331.1441; found, 331.1449.

### 4-(4-Chlorophenyl)-2,3-diphenyl-1,2,4-oxadiazolidin-5-one (**3aa**) {#sec4.3.27}

The product was obtained in a 83% yield (145 mg). White solid; mp 110--111 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.50--7.47 (m, 2H), 7.46--7.43 (m, 3H), 7.42--7.38 (m, 2H), 7.25--7.23 (m, 5H), 7.22--7.20 (m, 2H), 6.11 (s, 1H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 154.0, 149.2, 135.2, 134.1, 131.1, 130.3, 129.5, 129.4, 129.3, 127.2, 125.9, 122.3, 117.4, 86.4; HRMS (APCI) *m*/*z*: calcd for C~20~H~16~ClN~2~O~2~ \[M + H\]^+^, 351.0895; found, 351.0899.

### 2,3-Diphenyl-4-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazolidin-5-one (**3ab**) {#sec4.3.28}

The product was obtained in a 89% yield (171 mg). White solid; mp 111--112 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.54--7.44 (m, 9H), 7.43--7.38 (m, 2H), 7.27--7.26 (m, 1H), 7.25--7.20 (m, 2H), 6.20 (s, 1H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 154.0, 149.1, 138.84, 138.8, 134.9, 130.3, 129.53, 129.5, 127.0, 126.4, 126.36, 126.1, 119.8, 117.4, 86.0; HRMS (APCI) *m*/*z*: calcd for C~21~H~16~F~3~N~2~O~2~ \[M + H\]^+^, 385.1158; found, 385.1161.

### 2,3-Diphenyl-4-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazolidin-5-one (**3ac**) {#sec4.3.29}

The product was obtained in a 92% yield (186 mg). White solid; mp 93--94 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.52--7.48 (m, 2H), 7.47--7.44 (m, 3H), 7.42--7.38 (m, 2H), 7.35--7.33 (m, 2H), 7.25--7.20 (m, 3H), 7.13--7.11 (m, 2H), 6.13 (s, 1H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 154.1, 149.1, 146.3, 146.2, 135.2, 134.2, 130.3, 129.5, 129.4, 127.1, 125.9, 122.1, 121.8, 117.3, 86.5; HRMS (APCI) *m*/*z*: calcd for C~21~H~16~F~3~N~2~O~3~ \[M + H\]^+^, 401.1108; found, 401.1112.

### 4-(2-Nitrophenyl)-2,3-diphenyl-1,2,4-oxadiazolidin-5-one (**3ad**) {#sec4.3.30}

The product was obtained in a 72% yield (129 mg). Yellow solid; mp 147--148 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.03--7.97 (m, 1H), 7.57--7.51 (m, 2H), 7.48--7.29 (m, 7H), 7.23--7.12 (m, 3H), 7.91--6.86 (m, 1H), 6.09 (s, 1H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~): δ 153.6, 147.5, 145.9, 134.4, 133.8, 130.7, 130.4, 129.18, 129.17, 129.1, 128.8, 128.1, 126.2, 125.9, 118.6, 87.4; HRMS (APCI) *m*/*z*: calcd for C~20~H~16~N~3~O~4~ \[M + H\]^+^, 362.1135; found, 362.1139.

### *N*′-(4-Bromophenyl)-*N*-phenylbenzimidamide (**4a**) {#sec4.3.31}

The product was obtained in a 84% yield (147 mg). White solid; mp 123--124 °C; ^1^H NMR (400 MHz, CDCl~3~ + D~2~SO~4~): δ 7.40--7.33 (m, 1H), 7.26--7.18 (m, 3H), 7.14 (d, *J* = 8.7 Hz, 1H), 7.09--7.03 (m, 4H), 6.98--6.89 (m, 3H), 6.87--6.77 (m, 2H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~ + D~2~SO~4~): δ 135.56, 134.96, 132.44, 132.08, 130.47, 129.20, 129.03, 127.10, 126.81, 125.29, 120.60; HRMS (ESI-TOF) *m*/*z*: calcd for C~19~H~16~BrN~2~ \[M + H\]^+^, 351.0491; found, 351.0507.

### *N*′-(4-Chlorophenyl)-*N*-phenylbenzimidamide (**4b**) {#sec4.3.32}

The product was obtained in a 92% yield (140 mg). White solid; mp 120--121 °C; ^1^H NMR (400 MHz, CDCl~3~ + D~2~SO~4~): δ 14.16 (br s, 1H), 7.42 (t, *J* = 7.5 Hz, 1H), 7.28 (t, *J* = 7.8 Hz, 2H), 7.18 (d, *J* = 7.5 Hz, 2H), 7.13--7.01 (m, 5H), 6.90 (d, *J* = 6.8 Hz, 2H), 6.83 (d, *J* = 8.7 Hz, 2H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~ + D~2~SO~4~): δ 162.02, 136.41, 135.32, 132.17, 131.83, 130.11, 129.27, 128.92, 128.83, 126.42, 126.32, 126.03, 124.95; HRMS (ESI-TOF) *m*/*z*: calcd for C~19~H~16~ClN~2~ \[M + H\]^+^, 307.0997; found, 307.1003.

### *N*-Phenyl-*N*′-(4-(trifluoromethyl)phenyl)benzimidamide (**4c**) {#sec4.3.33}

The product was obtained in a 87% yield (147 mg). White solid; mp 110--111 °C; ^1^H NMR (400 MHz, CDCl~3~ + D~2~SO~4~): δ 14.28 (br s, 1H), 7.52--7.45 (m, 1H), 7.40--7.30 (m, 5H), 7.24 (d, *J* = 7.6 Hz, 2H), 7.18--7.09 (m, 3H), 7.02 (d, *J* = 8.4 Hz, 2H), 6.98--6.92 (m, 2H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~ + D~2~SO~4~): δ 162.24, 139.94, 136.24, 132.50, 130.12, 129.45, 128.93, 128.08, 127.76, 126.68, 126.14, 126.00, 125.97, 125.00, 124.59, 122.36; HRMS (ESI-TOF) *m*/*z*: calcd for C~20~H~16~F~3~N~2~ \[M + H\]^+^, 341.1260; found, 341.1277.

### *N*-Phenyl-*N*′-(4-(trifluoromethoxy)phenyl)benzimidamide (**4d**) {#sec4.3.34}

The product was obtained in a 88% yield (157 mg). White solid; mp 82--84 °C; ^1^H NMR (400 MHz, CDCl~3~ + D~2~SO~4~): δ 7.45 (t, *J* = 7.5 Hz, 1H), 7.31 (t, *J* = 7.8 Hz, 2H), 7.20 (d, *J* = 7.6 Hz, 2H), 7.16--7.03 (m, 3H), 7.01--6.85 (m, 6H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~ + D~2~SO~4~): δ 162.05, 146.90, 136.44, 135.39, 132.26, 130.08, 129.32, 128.86, 126.44, 126.33, 126.04, 124.92, 121.56, 121.31, 119.00; HRMS (ESI-TOF) *m*/*z*: calcd for C~20~H~16~F~3~N~2~O \[M + H\]^+^, 357.1209; found, 357.1217.

### *N*′-(4-Bromophenyl)-4-methyl-*N*-phenylbenzimidamide (**4e**) {#sec4.3.35}

The product was obtained in a 90% yield (163 mg). White solid; mp 121--122 °C; ^1^H NMR (400 MHz, CDCl~3~ + D~2~SO~4~): δ 7.27 (d, *J* = 8.6 Hz, 1H), 7.23--7.14 (m, 4H), 7.08 (d, *J* = 8.0 Hz, 2H), 7.05--6.94 (m, 2H), 6.87 (d, *J* = 8.6 Hz, 1H), 2.34 (s, 3H); ^13^C{^1^H} NMR (101 MHz, CDCl~3~ + D~2~SO~4~): δ 163.51, 144.00, 132.34, 130.60, 130.11, 129.27, 127.41, 126.67, 126.63, 125.16, 125.12, 121.58, 120.98, 21.73; HRMS (ESI-TOF) *m*/*z*: calcd for C~20~H~18~BrN~2~ \[M + H\]^+^, 365.0648; found, 365.0657.
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